Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 341-345

  Osorio, Marta ^a   Gracia, Elias ^a   Reigosa, Edmundo ^a   Hernandez, Julio ^b   de la Torre, Ana ^a   Saurez, Giselle ^c   Perez, Kirenia ^c   Viada, Carmen ^c   Cepeda, Meylán ^b   Carr, Adriana ^c   Ávila, Yisel ^d   Rodríguez, Migdalia ^d   Fernandez, Luis E ^c  

^a INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^b Celestino Hernández Hospital   (Cuba)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^d National Center of Clinical Trials   (Cuba)

Author keywords

Clinical trial; Ganglioside; Melanoma; N glycolyl GM3; Therapeutic vaccine

Indexed keywords

GANGLIOSIDE GM3; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; N GLYCOLYL GANGLIOSIDE GM3; PROTEOLIPOSOME; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CUTANEOUS MELANOMA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHEMA; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MULTICENTER STUDY; MYALGIA; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SKIN INDURATION; TREATMENT OUTCOME; VOMITING;

EID: 84867703148     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S22617     Document Type: Article

References (16)

1. Tsao H, Atkins M, Sober A. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1012.
2. Applebaum J, Reynolds S, Knispelruth J, Shapiro R. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. J Natl Cancer Inst. 1998;90(2):146-149.
3. Hodi F. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res. 2006;12:673-678.
4. Labrada M, Clavell M, Bebelagua Y, et al. Direct validation of NGcGM3ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther. 2010;10(2):153-162.
5. Fernandez LE, Gabri M, Guthman M, et al. NGcGM3ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol. 2010: 814397.
6. Marquina G, Waki H, Fernandez LE, et al. Gangliosides expressed in human breast cancer. Cancer Res. 1996;15:5165-5171.
7. Carr A, Rodriguez E, Arango MC, Camacho R, Osorio M, Gabri M. Immunotherapy of advanced breast cancer with heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol. 2003;21(6):1015-1021.
8. Osorio M, Gracia E, Rodriguez E, etal. Heterophilic NeuGcGM3ganglioside cancer vaccine in advanced melanoma patients. Results of a Phase Ib/IIa study. Cancer Biol Ther. 2008;7(4):488-495.
9. Hodi F, ÓDay S, McDermott D, etal. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
10. Khan M, Andrews S, Ismail-Khan R, etal. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006;13(3):211-217.
11. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006.
12. Eisenhauer E, Therasse P, Bogaerts J, etal. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
13. Blanco R, Rengifo E, Rengifo CE, Cedeño M, Frometa M, Carr A. Immunohistochemical reactivity of the 14F7monoclonal antibody raised against N-Glycolyl GM3ganglioside in some benign and malignant skin neoplasms. ISRN Dermatol. 2011:848909.
14. de Leon J, Fernandez A, Mesa C, Clavel M, Fernandez LE. Role of tumor-associated N-gycolylated variant of GM3ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother. 2006;55:443-450.
15. Estevez F, Carr A, Solorzano L, etal. Enhancement of the immune response to poorly immnunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 2000;18:190-197.
16. Cummins DL, Cummins JM, Pantle H, etal. Cutaneous malignant melanoma. Mayo Clin Proc. 2006;81(4):500-507.